SmithKline Beecham stops proton pump development
Executive Summary
Phase III clinical trials of the irreversible proton pump inhibitor pantoprazole (formerly designated SK&F-96022) have been halted in the U.K. and Europe, the company confirms Nov. 27. The drug was in Phase II in the U.S. SB says it "will not continue with [pantoprazole's] development" but notes that it has several follow-on compounds in preclinicals and early clinicals, including SK&F 96067 and SK&F 97574. SB stopped the studies after results of a preliminary analysis of a two-year rate carcinogenicity study showed "an increased incidence of hepatocellular neoplasia at doses of 50 mg/kg/day and 200 mg/kg/day," doses greater than those used in human clinicals. Pantoprazole was being co-developed by SB and Byk Gulden, which is continuing development of the drug, SB says. . . .
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth